AbbVie Q3 2026 Earnings: EPS More Than Doubles Year Over Year
AbbVie posted strong third-quarter 2026 results, with both GAAP and adjusted diluted EPS surging more than 100% despite a modest headwind from acquired R&D costs.
AbbVie reported a significant jump in third-quarter 2026 earnings, with diluted earnings per share on a GAAP basis reaching $2.37, a gain of more than 100 percent compared to the same period a year earlier. Adjusted diluted EPS came in at $3.82, also more than doubling year over year, signaling broad-based improvement across the pharmaceutical giant's operations.
The results were not without a drag. AbbVie noted that both EPS figures absorbed an unfavorable impact of $0.11 per share tied to acquired in-process research and development costs and milestone expenses — charges that commonly arise when a company advances or acquires pipeline assets. Excluding that headwind, underlying performance appeared even stronger.
Read more Citizens Financial Services Posts Q3 2026 Unaudited Results →
The more-than-doubling of earnings on both a reported and adjusted basis marks a notable rebound for the company, which has been working to diversify its revenue base following the loss of exclusivity on its blockbuster immunology drug Humira. Investors and analysts have closely watched AbbVie's newer immunology and oncology franchises as the primary drivers of future growth.
The quarter's results underscore the degree to which AbbVie's transition strategy appears to be gaining traction, as successor products absorb lost Humira revenue and contribute meaningfully to the bottom line. The IPR&D and milestone charges, while reducing headline EPS, reflect ongoing investment in next-generation therapies that could sustain long-term growth.
Continue reading at Earnings.
